Recommended Prophylactic Treatment for Sexually Transmitted Diseases in Females

Prevention Strategies

The Centers for Disease Control and Prevention recommends consistent and correct use of male latex condoms, which provides strong protection against various STDs, as demonstrated by multiple cohort studies, including those of serodiscordant couples 1, 2
The American College of Obstetricians and Gynecologists suggests that female condoms (Reality™) should be considered when male condoms cannot be used appropriately, as laboratory studies indicate they are effective mechanical barriers to viruses, including HIV 2
Condom failure usually results from inconsistent or incorrect use rather than breakage, with failure rates of approximately 2 per 100 condoms used 1, 2
Only water-based lubricants (e.g., K-Y Jelly, Astroglide, AquaLube) should be used with latex condoms, as oil-based lubricants can weaken latex and increase risk of failure 2, 3

The Centers for Disease Control and Prevention recommends that for women at high risk of STDs (age <25 years, new or multiple sex partners, unprotected sex), especially when follow-up cannot be ensured, empiric treatment may be considered 4
The recommended regimen for presumptive treatment is Azithromycin 1 g orally in a single dose OR Doxycycline 100 mg orally twice a day for 7 days, with a strength of evidence rated as strong 4
Concurrent treatment for N. gonorrhoeae should be considered if prevalence is high (>5%) in the patient population, based on moderate-quality evidence 4

The American College of Obstetricians and Gynecologists recommends annual screening for all sexually active women aged <25 years, even without symptoms, with a strength of evidence rated as strong 4
Older women with risk factors (new or multiple sex partners) should also be screened, based on moderate-quality evidence 4
Testing should include screening for chlamydia, gonorrhea, and syphilis, with a strength of evidence rated as strong 5

The Centers for Disease Control and Prevention recommends that sexual partners should be notified, examined, and treated for the identified or suspected STD, with a strength of evidence rated as strong 4
Both patient and partners should abstain from sexual intercourse until therapy is completed (7 days after a single-dose regimen or after completion of a 7-day regimen), based on moderate-quality evidence 4

The American College of Obstetricians and Gynecologists suggests that vaginal spermicides used alone (without condoms) reduce the risk for cervical gonorrhea and chlamydia but have not been established to protect against HIV infection, with a strength of evidence rated as moderate 1, 6
Diaphragm use has been shown to protect against cervical gonorrhea, chlamydia, and trichomoniasis in case-control and cross-sectional studies, based on low-quality evidence 1, 6
Women using hormonal contraception (oral contraceptives, Norplant, Depo-Provera), who have been surgically sterilized, or who have had hysterectomies should be counseled that these methods offer no protection against STDs, with a strength of evidence rated as strong 1
The Centers for Disease Control and Prevention recommends that hepatitis B vaccination is recommended for all unvaccinated patients being evaluated for an STD, with a strength of evidence rated as strong 2

The Centers for Disease Control and Prevention (CDC) states that use of internal (female) condoms can provide protection from transmission of STIs, although data are limited, representing the highest quality guideline evidence available 7, 8

When male condoms cannot be used appropriately, sex partners should consider using a female condom, based on the theoretical mechanical barrier protection demonstrated in laboratory settings and the absence of alternative female-controlled barrier methods with better evidence 9

If used consistently and correctly, the female condom should substantially reduce the risk for STDs 9
Protection against HIV infection should not be assumed from female condom use alone, given the limited clinical data 10, 11, 12, 13
The female condom has higher pregnancy failure rates (26% estimated 12-month failure rate) compared to male condoms, which may reflect challenges with consistent and correct use 10, 11, 12, 13

Male latex condoms, when used consistently and correctly, provide stronger documented protection against STIs based on multiple cohort studies, including serodiscordant couples 7, 8
Vaginal spermicides alone reduce risk for cervical gonorrhea and chlamydia but offer no established protection against HIV 9, 10, 11, 12, 13
Diaphragms protect against cervical gonorrhea, chlamydia, and trichomoniasis in case-control studies, but protection against HIV should not be assumed 10, 11, 12, 13
Hormonal contraceptives, surgical sterilization, and hysterectomy offer no protection against STIs 9, 10, 11, 12, 13

The evidence base for female condoms is primarily laboratory-derived, not from clinical effectiveness studies, and patients should not be counseled that they provide equivalent protection to male condoms based on clinical trial data 7, 8, 9